Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK
Published in EBioMedicine
Methodology
Two-centre open-label pilot of intermittent dasatinib 100 mg/day plus quercetin 1250 mg/day, three days per week for three weeks, in idiopathic pulmonary fibrosis
Key Findings
Retention was 100% and physical function measures (6-minute walk distance, gait speed, chair stands) improved significantly; adverse events were mostly mild to moderate.
Conclusions
Senolytic therapy was feasible in a senescence-associated disease and improved physical function measures.
Limitations
Open-label, uncontrolled, tiny sample, functional outcomes vulnerable to placebo and learning effects; quercetin not tested alone.
Supplements Studied
Physical function evaluated as 6-min walk distance, 4-m gait speed, and chair-stands time was significantly and clinically-mean
Outcomes Measured
Physical function evaluated as 6-min walk distance, 4-m gait speed, and chair-stands time was significantly and clinically-mean
Study Details
Access Study
Disclosures
Funding
NIH and foundations
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.